当代心脏病学中的β阻塞剂:是否更好把它们扔掉?
Javaid Ahmad Dar1, John Roshan Jacob2
1Department of Cardiology, Christian Medical College, Vellore, India. javaid985@gmail.com.
Korean circulation journal
|April 24, 2024
概括
贝塔阻断剂虽然对心力衰竭有降低射出分数 (HFrEF) 有益,但可能被过度使用. 目前的数据表明,在其他心血管疾病中,潜在的危害包括增加中风风险和减少运动能力.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 贝塔抑制剂广泛用于心血管疾病,包括高血压,冠状动脉疾病 (CAD) 和心力衰竭 (HF).
- 它们在心力衰竭与减少喷射分数 (HFrEF) 中的确定的疗效导致了广泛的临床应用.
研究的目的:
- 批判性地审查当前的适用性和β阻断剂的临床效用.
- 评估贝塔抑制剂在超出HFrEF范围的各种心血管疾病中使用的潜在风险与益处.
主要方法:
- 对现有数据和临床证据的系统审查,这些数据和临床证据涉及使用β阻塞剂.
- 对研究β阻塞剂在高血压,心力衰竭与保留喷射分数 (HFpEF),稳定的CAD和心房动 (AF) 的研究进行了批判性分析.
主要成果:
- 在高血压患者中,β抑制剂与中风风险增加和心房 (AF) 相关.
- 在HFpEF中,β抑制剂与运动能力下降有关.
- 在稳定的CAD或心肌梗塞中使用β抑制剂没有观察到死亡益处,心肌梗塞与正常的缩功能.
结论:
- 在诸如HFpEF,稳定的CAD和高血压等条件下,β抑制剂可能会被过度处方.
- 在HFrEF中观察到的好处可能不会转化为其他心血管疾病,可能会造成更多的伤害而不是好处.
相关概念视频
Adrenergic Antagonists: ɑ and β-Receptor Blockers
442
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
442
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
783
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
783
Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
592
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
592
Antihypertensive Drugs: Types of β-Blockers
657
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
657
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
741
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
741


